ES2900025T3 - Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo - Google Patents

Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo Download PDF

Info

Publication number
ES2900025T3
ES2900025T3 ES15838075T ES15838075T ES2900025T3 ES 2900025 T3 ES2900025 T3 ES 2900025T3 ES 15838075 T ES15838075 T ES 15838075T ES 15838075 T ES15838075 T ES 15838075T ES 2900025 T3 ES2900025 T3 ES 2900025T3
Authority
ES
Spain
Prior art keywords
drug
wafer
hydrophobic polymer
nanomesh
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15838075T
Other languages
English (en)
Spanish (es)
Inventor
Shikha P Barman
Moli Liu
Koushik Barman
Kevin L Ward
Brendan Hackett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integral Biosystems LLC
Original Assignee
Integral Biosystems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems LLC filed Critical Integral Biosystems LLC
Application granted granted Critical
Publication of ES2900025T3 publication Critical patent/ES2900025T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
ES15838075T 2014-09-06 2015-09-08 Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo Active ES2900025T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462046918P 2014-09-06 2014-09-06
PCT/US2015/048795 WO2016037169A1 (en) 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye

Publications (1)

Publication Number Publication Date
ES2900025T3 true ES2900025T3 (es) 2022-03-15

Family

ID=55440434

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15838075T Active ES2900025T3 (es) 2014-09-06 2015-09-08 Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo

Country Status (12)

Country Link
US (2) US9931306B2 (enExample)
EP (1) EP3188688B1 (enExample)
JP (2) JP7026507B2 (enExample)
KR (1) KR102456032B1 (enExample)
CN (2) CN106604695B (enExample)
AU (2) AU2015311637B2 (enExample)
CA (1) CA2960213C (enExample)
ES (1) ES2900025T3 (enExample)
MY (1) MY178327A (enExample)
SG (1) SG11201701714RA (enExample)
WO (1) WO2016037169A1 (enExample)
ZA (2) ZA201701467B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye
WO2017062770A1 (en) * 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
CA3038115A1 (en) * 2016-09-30 2018-04-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
WO2018067882A1 (en) 2016-10-05 2018-04-12 Titan Pharmaceuticals, Inc. Implantable devices for drug delivery with reduced burst release
EP3630024B1 (en) * 2017-05-22 2022-04-06 California Institute of Technology Small molecule transport device with anti-condensation filler for drug delivery or waste removal
JP2020527591A (ja) * 2017-07-17 2020-09-10 ウルフクリーク バイオテック プライベート リミテッド 活性薬剤送達のための微粒子製剤
JP7373207B2 (ja) 2018-03-01 2023-11-02 バー‐イラン、ユニバーシティー 眼の状態の矯正に使用するためのシステム、方法、及び材料組成物
MA52774A (fr) * 2018-06-05 2021-04-14 Corneat Vision Ltd Timbre de greffe ophtalmique synthétique
CN109853054A (zh) * 2019-02-27 2019-06-07 上海交通大学医学院附属第九人民医院 一种同轴静电纺丝三维打印生物支架的装置及搭建方法
EP3701974B1 (en) * 2019-02-28 2024-08-28 Agency for Science, Technology and Research A material suitable for use as a vitreous substitute and related methods
CA3132635A1 (en) * 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
WO2020198798A1 (en) * 2019-04-02 2020-10-08 Cytomatrix Limited A composition for the delivery of biologically active agents and uses thereof
TWI826685B (zh) 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
CA3149866A1 (en) 2019-10-24 2021-04-29 Denis E. Labombard Ocular device and drug delivery system, with case
BR112022011067A2 (pt) * 2019-12-10 2022-08-23 Alcon Inc Insertos oculares poliméricos dissolvíveis com um polímero biodegradável
EP4142664A4 (en) * 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
KR102467288B1 (ko) * 2020-06-09 2022-11-17 동국대학교 산학협력단 결막 접촉용 약물 전달기
EP3928805A1 (en) * 2020-06-26 2021-12-29 Royal College of Surgeons in Ireland A device for use in the delivery of an active agent
US20220160668A1 (en) * 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
WO2022250977A1 (en) * 2021-05-26 2022-12-01 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN114869862A (zh) * 2022-04-24 2022-08-09 温州医科大学附属眼视光医院 一种带引流功能的青光眼手术缓释抗瘢痕膜及制备方法
AU2024330194A1 (en) * 2023-08-31 2026-04-02 University Of Tennessee Research Foundation Sustained release ocular implants
TW202547517A (zh) * 2024-06-06 2025-12-16 美商視爾普斯眼科公司 用於治療眼部疾病之組合物及方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5177168A (en) * 1989-10-17 1993-01-05 Polymer Technology Corp. Polymeric compositions useful in oxygen permeable contact lenses
JPH10509696A (ja) 1994-10-12 1998-09-22 フォーカル， インコーポレイテッド 生分解性ポリマーを介する標的化送達
US8273366B2 (en) 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
CA2609687C (en) * 2005-05-24 2014-04-22 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens and methods of use
AU2006348901C1 (en) * 2006-09-28 2013-11-14 Essity Hygiene And Health Aktiebolag Absorbent article, belt structure, manufacturing method for a belt structure and manufacturing method for an absorbent article
US8614103B2 (en) * 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
CA2670944A1 (en) * 2006-12-18 2008-06-26 Alcon Research, Ltd. Devices and methods for ophthalmic drug delivery
US8974814B2 (en) * 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
US8361492B2 (en) * 2008-04-29 2013-01-29 Ocugenics, LLC Drug delivery system and methods of use
US8083347B2 (en) 2008-04-29 2011-12-27 Ocugenics, LLC Drug delivery system and methods of use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20100291182A1 (en) 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US8961600B2 (en) * 2009-06-25 2015-02-24 Optonol Ltd. Method of using a fiber matrix for maintaining space in soft tissues
KR102337046B1 (ko) 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US20110229551A1 (en) * 2010-03-17 2011-09-22 Notus Laboratories, Inc. Drug delivery compositions and methods using nanofiber webs
US9028860B2 (en) * 2010-04-28 2015-05-12 Poly-Med, Inc. Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery
WO2012114138A1 (fr) * 2011-02-21 2012-08-30 Cerebel-Invest Sa Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active
EP3494959A3 (en) 2011-04-29 2019-09-11 Allergan, Inc. Sustained release latanoprost implant
CA2848397C (en) 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
CN203089455U (zh) * 2013-02-01 2013-07-31 浙江大学医学院附属第二医院 襻上镶嵌有药物缓释微囊的人工晶状体
US9931306B2 (en) * 2014-09-06 2018-04-03 Integral Biosystems Llc Methods and biocompatible compositions to achieve sustained drug release in the eye

Also Published As

Publication number Publication date
AU2019250153B2 (en) 2021-02-04
JP2022001582A (ja) 2022-01-06
CN106604695A (zh) 2017-04-26
MY178327A (en) 2020-10-08
EP3188688A1 (en) 2017-07-12
JP7026507B2 (ja) 2022-02-28
SG11201701714RA (en) 2017-04-27
US20170296483A1 (en) 2017-10-19
KR102456032B1 (ko) 2022-10-18
US9931306B2 (en) 2018-04-03
US20180280313A1 (en) 2018-10-04
JP2017526655A (ja) 2017-09-14
AU2019250153A1 (en) 2019-10-31
EP3188688A4 (en) 2018-07-25
ZA201705792B (en) 2018-12-19
WO2016037169A1 (en) 2016-03-10
AU2015311637B2 (en) 2019-07-18
AU2015311637A1 (en) 2017-03-23
KR20170052582A (ko) 2017-05-12
CA2960213A1 (en) 2016-03-10
CN106604695B (zh) 2018-10-23
US10328033B2 (en) 2019-06-25
EP3188688B1 (en) 2021-11-03
CN109481447A (zh) 2019-03-19
CA2960213C (en) 2023-03-28
ZA201701467B (en) 2018-04-25
NZ729467A (en) 2024-04-26

Similar Documents

Publication Publication Date Title
AU2019250153B2 (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
CN111743878B (zh) 用于眼科应用和/或其它应用的组合物以及方法
JP6100782B2 (ja) 緑内障および高眼圧症を治療するための活性剤の徐放送達
JP2021038251A (ja) 改善された粘膜輸送を示す医薬用ナノ粒子
Desai et al. Ophthalmic and otic drug administration: novel approaches and challenges
JP2023133438A (ja) 眼薬徐放性製剤およびその利用
Yang et al. Intravitreal administration of dexamethasone-loaded PLGA-TPGS nanoparticles for the treatment of posterior segment diseases
Mythili et al. Ocular drug delivery system–an update review
Kaushik et al. Novel approaches in ocular drug delivery-A revolution
Dogra et al. Nanoformulations for ocular delivery of drugs-a patent perspective
Jani et al. Ocular drug delivery systems
Chaudhary et al. Nano-formulations: Recent Trends for Ocular Bioavailability Enhancement.
HK40003833A (zh) 用於在眼中实现持续药物释放的方法和生物相容性组合物
Pravin et al. Ocular Drug Delivery and Novel Formulations: A Review
HK1235660B (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
Herrero-Vanrell et al. Ocular pharmacokinetic drug, bioavailability and intraocular drug delivery systems
Tawfik Dual Drug-Loaded Electrospun Nanofibres for the Treatment of Corneal Diseases
Chu et al. Innovative Drug Delivery Systems for the Treatment of Glaucoma
Capítulo Nanoparticles as Ocular Drug Delivery Systems
HK40039406B (en) Compositions and methods for ophthalmic and/or other applications
JP2015074641A (ja) 眼内薬物送達デバイスおよび付随する方法
HK40039406A (en) Compositions and methods for ophthalmic and/or other applications
Khoee et al. Ophthalmic Drug Delivery: Polymer Systems for
HK1226949B (en) Compositions and methods for ophthalmic and/or other applications
HK1226949A1 (en) Compositions and methods for ophthalmic and/or other applications